Compare AIP & ALMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AIP | ALMR |
|---|---|---|
| Founded | 2003 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Laboratory Analytical Instruments |
| Sector | Technology | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.5B |
| IPO Year | 2021 | 2026 |
| Metric | AIP | ALMR |
|---|---|---|
| Price | $31.53 | $28.41 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $16.83 | N/A |
| AVG Volume (30 Days) | ★ 599.6K | 199.9K |
| Earning Date | 05-12-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 4.65 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $70,579,000.00 | N/A |
| Revenue This Year | $30.24 | N/A |
| Revenue Next Year | $19.50 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 22.27 | N/A |
| 52 Week Low | $8.42 | $21.58 |
| 52 Week High | $50.26 | $29.43 |
| Indicator | AIP | ALMR |
|---|---|---|
| Relative Strength Index (RSI) | N/A | N/A |
| Support Level | N/A | N/A |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.00 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 0.00 |
Arteris Inc is a provider of semiconductor system IP, including interconnect and other intellectual property, (collectively, System IP) technology. Its IP technology manages the on-chip communications and IP block deployments in System-on-Chip (SoC) semiconductors and systems of chiplets. Its proprietary System IP solutions achieve this by connecting client IP blocks such as processors, memories, artificial intelligence/machine learning (AI/ML) accelerators, graphics subsystems, safety and security, and other input/output subsystems (I/Os) via multiple Network-on-Chips (NoCs). The company operates in Americas, Asia Pacific and Europe, Middle East, out of which it derives maximum its revenue from Asia Pacific.
Alamar Biosciences Inc is a proteomics company engaged in protein detection and analysis. The company has developed its own NULISA (NUcleic Acid Linked Immuno-Sandwich Assay) technology as the foundation of its Precision Proteomics platform enabling the detection and quantification of protein biomarkers in a single sample with ultra-high sensitivity and high specificity, even from very small volumes of biofluid. The company operates in single segment and focuses on developing a good sensitive proteomic liquid biopsy platform and sells instruments, consumables, and services based on this platform to enable early detection of diseases. The products of the company includes NULISAseq Panels, NULISAqpcr Assays, and others.